Cargando…

Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion

Due to their lower production cost compared with monoclonal antibodies, single-chain variable fragments (scFvs) have potential for use in several applications, such as for diagnosis and treatment of a range of diseases, and as sensor elements. However, the usefulness of scFvs is limited by inhomogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Natsuki, Noi, Kentaro, Weng, Lidong, Kobashigawa, Yoshihiro, Miyazaki, Hiromi, Wakeyama, Yukari, Takaki, Michiyo, Nakahara, Yusuke, Tatsuno, Yuka, Uchida-Kamekura, Makiyo, Suwa, Yoshiaki, Sato, Takashi, Ichikawa-Tomikawa, Naoki, Nomizu, Motoyoshi, Fujiwara, Yukio, Ohsaka, Fumina, Saito, Takashi, Maenaka, Katsumi, Kumeta, Hiroyuki, Shinya, Shoko, Kojima, Chojiro, Ogura, Teru, Morioka, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151396/
https://www.ncbi.nlm.nih.gov/pubmed/28994732
http://dx.doi.org/10.3390/molecules22101695
_version_ 1783357143566516224
author Fukuda, Natsuki
Noi, Kentaro
Weng, Lidong
Kobashigawa, Yoshihiro
Miyazaki, Hiromi
Wakeyama, Yukari
Takaki, Michiyo
Nakahara, Yusuke
Tatsuno, Yuka
Uchida-Kamekura, Makiyo
Suwa, Yoshiaki
Sato, Takashi
Ichikawa-Tomikawa, Naoki
Nomizu, Motoyoshi
Fujiwara, Yukio
Ohsaka, Fumina
Saito, Takashi
Maenaka, Katsumi
Kumeta, Hiroyuki
Shinya, Shoko
Kojima, Chojiro
Ogura, Teru
Morioka, Hiroshi
author_facet Fukuda, Natsuki
Noi, Kentaro
Weng, Lidong
Kobashigawa, Yoshihiro
Miyazaki, Hiromi
Wakeyama, Yukari
Takaki, Michiyo
Nakahara, Yusuke
Tatsuno, Yuka
Uchida-Kamekura, Makiyo
Suwa, Yoshiaki
Sato, Takashi
Ichikawa-Tomikawa, Naoki
Nomizu, Motoyoshi
Fujiwara, Yukio
Ohsaka, Fumina
Saito, Takashi
Maenaka, Katsumi
Kumeta, Hiroyuki
Shinya, Shoko
Kojima, Chojiro
Ogura, Teru
Morioka, Hiroshi
author_sort Fukuda, Natsuki
collection PubMed
description Due to their lower production cost compared with monoclonal antibodies, single-chain variable fragments (scFvs) have potential for use in several applications, such as for diagnosis and treatment of a range of diseases, and as sensor elements. However, the usefulness of scFvs is limited by inhomogeneity through the formation of dimers, trimers, and larger oligomers. The scFv protein is assumed to be in equilibrium between the closed and open states formed by assembly or disassembly of VH and VL domains. Therefore, the production of an scFv with equilibrium biased to the closed state would be critical to overcome the problem in inhomogeneity of scFv for industrial or therapeutic applications. In this study, we obtained scFv clones stable against GA-pyridine, an advanced glycation end-product (AGE), by using a combination of a phage display system and random mutagenesis. Executing the bio-panning at 37 °C markedly improved the stability of scFvs. We further evaluated the radius of gyration by small-angle X-ray scattering (SAXS), obtained compact clones, and also visualized open–close dynamics of these scFvs by high-speed atomic force microscopy (HS-AFM), revealing that one of the compact clones was biased to the closed state. Finally, nuclear magnetic resonance (NMR) analysis revealed that peak intensity and line width became homogeneous, supporting that dynamic features and/or formation of oligomers was improved in the thus-obtained clone. These findings should contribute to the future industrial and therapeutic use of scFvs.
format Online
Article
Text
id pubmed-6151396
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61513962018-11-13 Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion Fukuda, Natsuki Noi, Kentaro Weng, Lidong Kobashigawa, Yoshihiro Miyazaki, Hiromi Wakeyama, Yukari Takaki, Michiyo Nakahara, Yusuke Tatsuno, Yuka Uchida-Kamekura, Makiyo Suwa, Yoshiaki Sato, Takashi Ichikawa-Tomikawa, Naoki Nomizu, Motoyoshi Fujiwara, Yukio Ohsaka, Fumina Saito, Takashi Maenaka, Katsumi Kumeta, Hiroyuki Shinya, Shoko Kojima, Chojiro Ogura, Teru Morioka, Hiroshi Molecules Article Due to their lower production cost compared with monoclonal antibodies, single-chain variable fragments (scFvs) have potential for use in several applications, such as for diagnosis and treatment of a range of diseases, and as sensor elements. However, the usefulness of scFvs is limited by inhomogeneity through the formation of dimers, trimers, and larger oligomers. The scFv protein is assumed to be in equilibrium between the closed and open states formed by assembly or disassembly of VH and VL domains. Therefore, the production of an scFv with equilibrium biased to the closed state would be critical to overcome the problem in inhomogeneity of scFv for industrial or therapeutic applications. In this study, we obtained scFv clones stable against GA-pyridine, an advanced glycation end-product (AGE), by using a combination of a phage display system and random mutagenesis. Executing the bio-panning at 37 °C markedly improved the stability of scFvs. We further evaluated the radius of gyration by small-angle X-ray scattering (SAXS), obtained compact clones, and also visualized open–close dynamics of these scFvs by high-speed atomic force microscopy (HS-AFM), revealing that one of the compact clones was biased to the closed state. Finally, nuclear magnetic resonance (NMR) analysis revealed that peak intensity and line width became homogeneous, supporting that dynamic features and/or formation of oligomers was improved in the thus-obtained clone. These findings should contribute to the future industrial and therapeutic use of scFvs. MDPI 2017-10-10 /pmc/articles/PMC6151396/ /pubmed/28994732 http://dx.doi.org/10.3390/molecules22101695 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fukuda, Natsuki
Noi, Kentaro
Weng, Lidong
Kobashigawa, Yoshihiro
Miyazaki, Hiromi
Wakeyama, Yukari
Takaki, Michiyo
Nakahara, Yusuke
Tatsuno, Yuka
Uchida-Kamekura, Makiyo
Suwa, Yoshiaki
Sato, Takashi
Ichikawa-Tomikawa, Naoki
Nomizu, Motoyoshi
Fujiwara, Yukio
Ohsaka, Fumina
Saito, Takashi
Maenaka, Katsumi
Kumeta, Hiroyuki
Shinya, Shoko
Kojima, Chojiro
Ogura, Teru
Morioka, Hiroshi
Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion
title Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion
title_full Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion
title_fullStr Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion
title_full_unstemmed Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion
title_short Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion
title_sort production of single-chain fv antibodies specific for ga-pyridine, an advanced glycation end-product (age), with reduced inter-domain motion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151396/
https://www.ncbi.nlm.nih.gov/pubmed/28994732
http://dx.doi.org/10.3390/molecules22101695
work_keys_str_mv AT fukudanatsuki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT noikentaro productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT wenglidong productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT kobashigawayoshihiro productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT miyazakihiromi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT wakeyamayukari productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT takakimichiyo productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT nakaharayusuke productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT tatsunoyuka productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT uchidakamekuramakiyo productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT suwayoshiaki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT satotakashi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT ichikawatomikawanaoki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT nomizumotoyoshi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT fujiwarayukio productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT ohsakafumina productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT saitotakashi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT maenakakatsumi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT kumetahiroyuki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT shinyashoko productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT kojimachojiro productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT ogurateru productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion
AT moriokahiroshi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion